Randomized placebo control study of insulin sensitizers (Metformin and Pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort)

Table 3 Adverse events observed during the study in placebo, metformin and pioglitazone treatment groups in topical treatment arm

Adverse Event	Placebo (N = 23)	Metformin (N = 21)	Pioglitazone (N = 16)	P value (Fischer’s Exact test)
Redness	1	1	0	>0.99^a, >0.99^b,>0.99^c
Pain	1	0	0	>0.99^a, >0.99^b,>0.99^c
Hyperpigmentation	7	5	4	0.74^a, >0.99^b > 0.99^c
Hypopigmentation	0	1	1	0.477^a, 0.41^b > 0.99^c
Exacerbation	2	3	0	0.658^a, 0.503^b, 0.243^c
Hypothyroidism	1	0	0	>0.99^a, >0.99^b
Edema	0	0	2	0.162^b, 0.180^c
c/o Weight Gain	0	0	2	0.162^b, 0.180^c
Anemia	0	0	0	-
Abdominal Pain	0	1	0	0.477^a, >0.99^c
Headache	0	0	0	-
Gastritis	0	0	0	-
Nausea	0	0	0	-
Vomiting	0	0	0	-
Dizziness	0	0	0	-
Diarrhea	0	1	0	0.477^a, >0.99^c
Heartburn	0	1	0	0.477^a, >0.99^c
>3 times SGOT/SGPT	0	0	0	-
Slight increase in SGOT/SGPT	0	0	0	-
Increased TLC	0	0	0	-
Weight gain > 1 kg	8	3	8	0.169^a, 0.509^b, 0.030^c
Recurrence after 3 months	4	6	5	0.377^a, 0.312^b, 0.860^c

Inter group comparison between groups was done by Fischer’s Exact test; p – value ≤ 0.05 was considered statistically significant
^a placebo vs metformin
^b placebo vs pioglitazone
^c metformin vs pioglitazone

ISSN: 1471-5945